Pharma


  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Leqembi sales inch higher; Spark’s pivot leads to layoffs

    Sales data suggest forecasts for the Alzheimer’s drug may be in reach. Elsewhere, Ipsen is licensing an ADC and Novartis is closing a San Diego site.

    By BioPharma Dive staff • July 12, 2024
  • BMS corporate sign
    Image attribution tooltip
    Courtesy of BMS
    Image attribution tooltip

    Bristol Myers’ leukemia blockbuster set to face generic rivals

    Patent litigation has opened the door to generic copies of Bristol Myers’ Sprycel arriving in the U.S. as soon as September.

    By Amy Baxter • July 12, 2024
  • Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Explore the Trendline
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
    Image attribution tooltip
    Trendline

    COVID-19 vaccines

    The urgency of the pandemic’s first two years is giving way to questions of how to sustain public health responses and prepare for what could come next. In the U.S., health officials are urging booster shots and preparing for private sector distribution of vaccines.

    By BioPharma Dive staff
  • People pass an office building with signage spelling Pfizer in New York City.
    Image attribution tooltip
    George Clerk via Getty Images
    Image attribution tooltip

    Pfizer thinks it found its obesity pill

    Far behind companies like Novo and Eli Lilly, Pfizer hopes the version of the drug, danuglipron, that it’s chosen to advance can break into the ultra-lucrative market for weight-loss medicines. 

    By July 11, 2024
  • A person holds an insulin pen
    Image attribution tooltip
    agrobacter via Getty Images
    Image attribution tooltip

    Novo’s once-weekly insulin rejected by FDA

    The FDA’s decision to turn back the drugmaker’s new insulin product narrows Novo’s lead in the U.S. over Eli Lilly, which has a similar diabetes treatment in late-stage testing. 

    By Kristin Jensen • July 11, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    AbbVie names new R&D head; Arcutis eczema cream approved

    Roopal Thakkar will succeed Tom Hudson as AbbVie’s top scientist. Elsewhere, Skyhawk is advancing its Huntington’s drug and Zevra is preparing for an FDA advisory committee meeting.

    By BioPharma Dive staff • July 10, 2024
  • Pfizer's logo cast in metal.
    Image attribution tooltip
    Jeenah Moon via Getty Images
    Image attribution tooltip

    Pfizer research chief Dolsten to step down, with company at a crossroads

    The company has begun searching for a successor to Dolsten, who oversaw more than 35 drug and vaccine approvals but also some notable setbacks during his time as Pfizer’s top scientist.

    By July 9, 2024
  • A sign shows the logo of Eli Lilly's Research Laboratories
    Image attribution tooltip
    jetcityimage via Getty Images
    Image attribution tooltip

    Lilly to buy Morphic in $3B bet on inflammation drug

    The deal would hand Lilly an experimental pill that could one day rival Takeda's blockbuster medicine Entyvio as a treatment for inflammatory bowel disease.

    By July 8, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Ligand to buy Apeiron; Roche reports another TIGIT setback

    Acquiring Apeiron will hand Ligand royalty rights on the neuroblastoma drug Qarziba. Elsewhere, CSL reported the first commercial treatment of patients in Europe with its gene therapy Hemgenix.

    By BioPharma Dive staff • July 8, 2024
  • Employees of CureVac work in a laboratory
    Image attribution tooltip
    Courtesy of CureVac
    Image attribution tooltip

    CureVac cuts jobs, licenses out vaccines to GSK

    The mRNA specialist plans to eliminate 30% of its workforce as part of a restructuring that will prioritize “high-value” projects like its cancer vaccines.

    By July 3, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Beacon raises $170M for eye gene therapy; J&J confirms Carvykti survival benefit

    Forbion led the startup’s Series B round. Elsewhere, Vertex got an FDA decision date for its “vanza triple” and Dupixent won a marketing green light in Europe for COPD.

    By BioPharma Dive staff • July 3, 2024
  • A sign showing the Eisai logo outside of a building
    Image attribution tooltip
    Courtesy of Eisai
    Image attribution tooltip

    Eisai and Bristol Myers cancel cancer ADC deal

    The Japan-based drugmaker said its U.S. partner’s “portfolio prioritization efforts” led to the termination. It will refund part of an upfront payment.

    By July 1, 2024
  • HPAI H5N1 virus
    Image attribution tooltip
    koto_feja via Getty Images
    Image attribution tooltip
    Sponsored by Nelson Labs

    The right viral safety program can guard against costly bioburden incidents in biopharma development

    Viral contamination threatens biopharmaceutical development, making viral clearance and safety essential for risk mitigation.

    July 1, 2024
  • A wall showing a Merck & Co. logo in Kenilworth, New Jersey
    Image attribution tooltip
    Courtesy of Merck & Co.
    Image attribution tooltip

    Merck’s pneumococcal vaccine gets CDC panel backing

    Advisers to the agency unanimously recommended use of Capvaxive in older adults and in certain younger ones, putting it in the same tier as Pfizer's competing Prevnar shot.

    By June 28, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar

    European drug regulators voted for a third time not to renew the approval of Translarna. Elsewhere, Sanofi invested in a brain disease biotech and Esperion sold royalties to help pay off a loan. 

    By BioPharma Dive staff • June 28, 2024
  • A podium showing the logo for the Centers for Disease Control and Prevention is seen.
    Image attribution tooltip
    Kevin C. Cox via Getty Images
    Image attribution tooltip
    RSV vaccines

    RSV vaccine makers’ shares fall as CDC adjusts shot guidance

    The new guidance more strongly urges vaccination in adults who are older or at higher risk, but removes a prior recommendation for adults aged 60 to 74 years without certain risk factors.

    By June 27, 2024
  • A sign reading Novo Nordisk is seen on the side of a building.
    Image attribution tooltip
    Victor Golmer via Getty Images
    Image attribution tooltip

    Novo nixes trial of blood pressure drug it bought in $1.3B deal

    The failure of a Phase 3 study led the Wegovy maker to take an accounting charge that will hit its operating profit growth this year.

    By June 26, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Zealand hauls in $1B off obesity drug data; Curie.bio zeroes in on Series A’s

    Zealand capitalized on a stock surge following the release of early study results. Elsewhere, U.S. regulators rejected an AbbVie medicine and another well-funded AI drug discovery startup emerged. 

    By BioPharma Dive staff • June 26, 2024
  • A large group of dosing pens for subcutaneous injection of anti-obesity medication piled in a heap.
    Image attribution tooltip
    aprott via Getty Images
    Image attribution tooltip

    Novo to spend $4B on US plant, adding to obesity drug production push

    The planned facility in North Carolina is Novo’s latest multibillion-dollar investment in the manufacturing of weight loss drugs, demand for which continues to outstrip supply.

    By June 25, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Obesity drugs from Altimmune, Hengrui show potential; Lilly details Zepbound sleep apnea data

    The American Diabetes Association’s annual meeting provided a forum for early trial results on several would-be weight loss drug competitors.

    By BioPharma Dive staff • June 24, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs

    A medicine Jazz acquired in 2019 missed the goal of a Phase 2 study. Elsewhere, Vanda rejected two takeover bids and Ashibio emerged from stealth with an antibody licensed from Gilead.

    By BioPharma Dive staff • June 21, 2024
  • Amazon Pharmacy
    Image attribution tooltip
    Courtesy of Amazon
    Image attribution tooltip

    Amazon expands drug subscription program to Medicare members

    RxPass, which fills prescriptions for generic drugs, is now available to more than 50 million Medicare members after Amazon brought it into compliance with the insurance program’s regulatory standards.

    By Rebecca Pifer • June 20, 2024
  • The Merck & Co. sign at the company's building in Summit, New Jersey.
    Image attribution tooltip
    Kena Betancur via Getty Images
    Image attribution tooltip

    Merck wins FDA OK for vaccine rival to Pfizer’s pneumococcal shot

    The new vaccine, which Merck will sell as Capvaxive, will compete with Pfizer’s blockbuster Prevnar franchise.

    By June 18, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short

    Belharra will use its chemoproteomics technology to identify immune drugs for Sanofi. Elsewhere, Regenxbio mapped a regulatory path and Taysha shared updated results for its Rett treatment.

    By BioPharma Dive staff • June 18, 2024
  • Two researchers in safety goggles and lab coats work in a lab.
    Image attribution tooltip
    Permission granted by Kevin Trimmer/Ascidian Therapeutics
    Image attribution tooltip

    Roche partners with RNA editing biotech Ascidian

    While the Swiss pharma recently pruned its neurology drug pipeline, it has shown interest in the possibilities of RNA-focused approaches like what Ascidian is exploring.

    By June 18, 2024
  • A sign with the logo for the Takeda pharmaceutical company.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Takeda drug for rare types of epilepsy misses goal in late-stage trial

    Called soticlestat, the drug had seemed promising in earlier studies for people with Dravet and Lennox-Gastaut syndrome, enough to persuade Takeda to take on full rights to the drug.

    By June 17, 2024